Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit Review0929 has been discontinued.
View all Adrenergic β<sub>3</sub> Receptors products.The active metabolite of ZD 7114 (Cat. No. 0930).
Sold with the permission of AstraZeneca UK Ltd.
分子量 | 397.86 |
公式 | C19H23NO6.HCl |
储存 | Store at RT |
CAS Number | 140850-02-8 |
PubChem ID | 56972157 |
InChI Key | ISFZQNYGEYAUCR-RSAXXLAASA-N |
Smiles | O[C@H](COC2=CC=CC=C2)CNCCOC1=CC=C(OCC(O)=O)C=C1.Cl |
上方提供的技术数据仅供参考。批次相关数据请参见分析证书。
Tocris products are intended for laboratory research use only, unless stated otherwise.
参考文献是支持产品生物活性的出版物。
How (1993) β3Adrenergic agonists. Drugs Future 18 529
关键词: ICI 215,001 hydrochloride, ICI 215,001 hydrochloride supplier, β3-adrenoceptor, b3-adrenoceptor, β3-adrenergic, b3-adrenergic, agonists, Receptors, ICI215001, hydrochloride, AstraZeneca, Adrenergic, Beta-3, 0929, Tocris Bioscience
引用文献是使用了 Tocris 产品的出版物。 ICI 215,001 hydrochloride 的部分引用包括:
Suárez et al (2014) Oleoylethanolamide enhances β-adrenergic-mediated thermogenesis and white-to-brown adipocyte phenotype in epididymal white adipose tissue in rat. Dis Model Mech 7 129 PMID: 24159189
Littmann et al (2015) Recruitment of β-arrestin 1 and 2 to the β2-adrenoceptor: analysis of 65 ligands. PLoS One 355 183 PMID: 26306764
目前没有该产品的评论。 Be the first to review ICI 215,001 hydrochloride and earn rewards!
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*请注意,Tocris 仅会向正规科研企业/机构地址发送文献。
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.